Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Agid

Neurology

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Neurology|May 5, 1998
Levodopa: is toxicity a myth?Y Agid
Neurology|December 1, 1980
Is the mesocortical dopaminergic system involved in Parkinson disease?F Javoy-Agid, Y Agid
Neurology|April 1, 1986
Parkinson's disease: decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamenR Raisman, R Cash, Y Agid
Neurology|September 1, 1988
Does levodopa aggravate Parkinson's disease?J Blin, A M Bonnet, Y Agid
Neurology|September 1, 1986
Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson's disease, and Alzheimer's diseaseB Pillon, B Dubois, F Lhermitte, et al.
Neurology|May 1, 1991
Severity and specificity of cognitive impairment in Alzheimer's, Huntington's, and Parkinson's diseases and progressive supranuclear palsyB Pillon, B Dubois, A Ploska, et al.
Neurology|June 1, 1981
Bromocriptine and domperidone in the treatment of Parkinson diseaseN Quinn, A Illas, F Lhermitte, et al.
Neurology|February 1, 1994
Impaired simultaneous cognitive task performance in Parkinson's disease: a dopamine-related dysfunctionC Malapani, B Pillon, B Dubois, et al.
Neurology|May 1, 1996
Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease?P Damier, A Kastner, Y Agid, et al.
Neurology|September 1, 1982
Dopamine deficiency in the cerebral cortex in Parkinson diseaseB Scatton, L Rouquier, F Javoy-Agid, et al.
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Neurology|May 5, 1998
Levodopa: is toxicity a myth?Y Agid
Neurology|December 1, 1980
Is the mesocortical dopaminergic system involved in Parkinson disease?F Javoy-Agid, Y Agid
Neurology|April 1, 1986
Parkinson's disease: decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamenR Raisman, R Cash, Y Agid
Neurology|September 1, 1988
Does levodopa aggravate Parkinson's disease?J Blin, A M Bonnet, Y Agid
Neurology|September 1, 1986
Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson's disease, and Alzheimer's diseaseB Pillon, B Dubois, F Lhermitte, et al.
Neurology|May 1, 1991
Severity and specificity of cognitive impairment in Alzheimer's, Huntington's, and Parkinson's diseases and progressive supranuclear palsyB Pillon, B Dubois, A Ploska, et al.
Neurology|June 1, 1981
Bromocriptine and domperidone in the treatment of Parkinson diseaseN Quinn, A Illas, F Lhermitte, et al.
Neurology|February 1, 1994
Impaired simultaneous cognitive task performance in Parkinson's disease: a dopamine-related dysfunctionC Malapani, B Pillon, B Dubois, et al.
Neurology|May 1, 1996
Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease?P Damier, A Kastner, Y Agid, et al.
Neurology|September 1, 1982
Dopamine deficiency in the cerebral cortex in Parkinson diseaseB Scatton, L Rouquier, F Javoy-Agid, et al.
Pageof 7